Geron Stock Finishes Day up 36 Percent

Jan 23, 2009

∙ Paid

Geron stock closed at $7.09 today, up 36 percent with the biggest one-day gain in five years, according to Bloomberg.com.

Bloomberg said,

"The FDA’s action may help pave the way for other companies to get permission to start their own trials, said Christopher Thomas Scott, director of Stanford University’s Stem Cells in Society program.

"'Geron is a path…

Keep reading with a 7-day free trial

Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.